KDC-MN-1350 – Kodiac biolabs

Our opinion on this compoundEstablished workhorse

24/100

Mature cosmetic peptide blend with manufacturer-dominated evidence and limited utility as a standalone bench research compound

Look, Matrixyl 3000 is a cosmetic ingredient. Sederma launched it in the early 2000s and it’s now in essentially every premium anti-aging formulation on the market. Two palmitoylated matrikines: Pal-GHK, the palmitoylated cousin of the GHK we document separately as GHK-Cu (KDC-MN-007), and Pal-GQPR, an immunoglobulin-derived peptide that modulates IL-6-driven inflammation through a mechanism that hasn’t attracted much independent attention outside Sederma’s own research program.

The matrikine concept is solid. GHK-derived peptides signaling dermal fibroblasts to repair extracellular matrix — thats real, well-characterized biology. The dual-mechanism rationale is at least conceptually interesting: a matrix synthesis signal paired with an anti-inflammatory brake, addressing two complementary vectors of dermal aging simultaneously. The GQPR/IL-6 angle is genuinely the more novel piece; immunoglobulin-derived anti-inflammatory peptides remain underexplored in the dermal biology literature. We just wish someone other than Sederma was doing the exploring.

Evidence quality is where this struggles. The published efficacy data — measurable increases in skin firmness and reduced wrinkle depth at 8 weeks of twice-daily application — comes overwhelmingly from Sederma-sponsored studies. Independent academic replication is close to nonexistent in the peer-reviewed record. Thats not unusual for cosmetic ingredients, but it matters a great deal when we’re evaluating this as a research-library entry rather than a formulator’s catalog listing.

For bench use specifically, the blend format is a real liability. You can’t cleanly attribute an observed effect to Pal-GHK versus Pal-GQPR when both are present simultaneously at a fixed ratio you didn’t choose. If the goal is studying GHK matrikine biology, GHK-Cu is the better-characterized probe with decades of multi-lab literature behind it. If the goal is interrogating GQPR/IL-6 interactions, Pal-GQPR in isolation is the right tool. Matrixyl 3000 as a bundle is optimized for cosmetic formulation efficiency, not mechanistic clarity.

Honestly, researchers with genuine interest in matrikine biology or ECM signaling should look at GHK-Cu for the established literature base, or at more recent peptide bioregulators where mechanism is being actively interrogated by independent groups. Matrixyl 3000 as a blend is what goes in the face cream. The individual matrikine components are more interesting studied separately, and the evidence base here is too manufacturer-concentrated to support a serious independent research program.

Novelty: 20
Mechanism promise: 32
In-category differentiation: 25
Evidence quality: 22
Translational signal: 25
Research bench value: 20

Rationale Matrixyl 3000 is a 20-year-old Sederma formulation built on GHK, already documented in the Kodiac library as GHK-Cu (KDC-MN-007); the GQPR/IL-6 angle is the only genuinely underexplored piece, but Sederma owns that literature almost entirely. Evidence is overwhelmingly manufacturer-sponsored with negligible independent replication, and the fixed-blend format actively hampers mechanistic attribution in bench work.

Matrikine cosmetic peptide blend (Pal-GHK and Pal-GQPR)

A topical cosmetic blend of two palmitoylated matrikine peptides, palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR), formulated for collagen synthesis stimulation in cosmetic anti-aging applications.

Abstract

Matrixyl 3000 is a cosmetic ingredient blend developed by the French company Sederma (Croda) consisting of two palmitoylated matrikine peptides: palmitoyl tripeptide-1 (Pal-Gly-His-Lys; Pal-GHK; molecular weight approximately 578 Da; the palmitoylated version of the well-characterized matrikine GHK that is the basis of GHK-Cu, KDC-MN-007) and palmitoyl tetrapeptide-7 (Pal-Gly-Gln-Pro-Arg; Pal-GQPR; molecular weight approximately 619 Da). The matrikine concept describes short bioactive peptides released by enzymatic degradation of extracellular matrix proteins (collagens, elastin, laminin) that signal to dermal fibroblasts to repair the matrix; the matrikine signal is interpreted as a tissue-damage marker that drives compensatory matrix synthesis. GHK is the canonical collagen-promoting matrikine; the GQPR sequence is derived from immunoglobulin and inhibits IL-6-induced inflammatory cytokine production. The palmitoylation of both peptides anchors them in the lipid bilayer of the stratum corneum, substantially improving topical retention relative to the unmodified peptides and providing sustained cutaneous delivery. The pharmacological argument for the blend over either peptide alone is the dual mechanism: collagen synthesis stimulation through GHK signaling combined with anti-inflammatory and matrix-protective signaling through GQPR. Published manufacturer-sponsored studies report measurable increases in skin firmness, reduced wrinkle depth, and improved skin tone at 8 weeks of twice-daily topical application of 3 percent or 4 percent Matrixyl 3000 solutions. Independent academic replication is limited. The blend is sold as a cosmetic ingredient (not a regulated drug) in essentially all major cosmetic markets. Distinct from the original Matrixyl (palmitoyl pentapeptide-4, also known as Pal-KTTKS), which is a separate Sederma matrikine ingredient.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1350Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-1350

Matrixyl 3000

Abstract

Read the full monograph